Lin Y, Berdeja J, Raje N, et al. First-in-human multicenter study of BB2121 anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma: updated results. EHA 2017, abstract 142.
Mutaties in TP53, TET2 en RUNX1 voorspellen progressie bij laag- en intermediair-I-risico del(5q) MDS
mrt 2017 | MDS